Clinical performance of antigen-specific interferon-gamma assay for the diagnosis of latent tuberculosis in risky hospital-based populations;Aplicación clínica de una prueba de producción de interferón gamma para el diagnóstico de tuberculosis latente en poblaciones hospitalarias de riesgo

Medicina Clinica

Volumn 130, Issue 20, 2008, Pages 761-766

  Torres, Héctor E ^a   Zapico, Marta ^a   Vivas, Santiago ^a   Mostaza, José L ^a   Blanco, Julio ^a   Ruiz De Morales, José M G ^a  

^a HOSPITAL DE LEÓN   (Spain)

Author keywords

Adults; Diagnosis; Immunosuppression; Interferon gamma; Latent tuberculosis; QuantiFERON

Indexed keywords

ANTIGEN SPECIFIC INTERFERON GAMMA ASSAY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; EFFECTOR CELL; FEMALE; HEMODIALYSIS PATIENT; HOSPITAL PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; RISK ASSESSMENT; SERODIAGNOSIS; TUBERCULIN TEST; TUBERCULOSIS;

EID: 45249099329     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13121100     Document Type: Article

References (20)

1. Rey R, Ausina V, Casal M, Caylá JA, DeMarch P, Moreno S, et al. Situación actual de la tuberculosis en España. Una perspectiva sanitaria en precario respecto a los países desarrollados. Med Clin (Barc). 1995;105:703-7.
2. Cardona PJ, Ruiz-Manzano J. On the nature of Mycobacterium tuberculosis-latent bacilli. Eur Respir J. 2004;24:1044-51.
3. Gómez Rodríguez F, Bernal Bermúdez JA, García Egido A. Evaluación y tratamiento de la tuberculosis latente en el adulto. Med Clin (Barc). 2001;117:111-4.
4. Ferrara G, Losi M, D'Amico R, Roversi P, Piro R, Meacci M, et al. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet. 2006;367:1328-34.
5. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med. 2007;146:340-54.
6. NICE. Clinical Guideline 33. Tuberculosis: clinical diagnosis and management and measures for its prevention and control. London: National Institute for Health and Clinical Excellence; 2006. Disponible en: http//nice.org.uk/page.aspx? o= CG033NICE guideline
7. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep. 2005;54:49-55.
8. Enfermedades de transmisión respiratoria. Boletín Epidemiológico de Castilla y León. 2006;22:5-13.
9. Pai M, Riley L, Colford J. Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis. 2004;4:761-6.
10. Pai M, Lewinsohn D. Interferon-γ assays for tuberculosis: is anergy the Achilles' heel? Am J Respir Crit Care Med. 2005;172:519-21.
11. Kaufman SH. Immunity to intracellular bacteria. En: Paul WE, editor. Fundamental immunology. 3rd ed. New York: Raven Press; 1993. p. 1274.
12. Chen X, Zhou B, Li M, Deng Q, Wu X, Le X, et al. CD4+CD25+ FoxP3 regulatory T cells suppress Mycobacterium tuberculosis immunity in patients with active disease. Clin Immunol. 2007;123:50-9.
13. Dheda K, Lalvani A, Miller R, Scott G, Booth H, Johnson M, et al. Performance of a T-cell based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS. 2005;19:2038-41.
14. Kang YA, Lee HW, Yoon H, Cho B, Han SK, Shim Y, et al. Discrepancy between the tuberculin skin test and the whole-blood interferon γ assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis burden country. JAMA. 2005;293:2756-61.
15. Luetkemeyer A, Charlebois E, Flores L, Bangsberg D, Deekks S, Martin J, et al. Comparison of an interferon release assay with tuberculin skin testing in HIV infected individuals. Am J Respir Crit Care Med. 2007;175:737-42.
16. Pathan A, Wilkinson K, Klenerman P, McShane H, Davidson R, Pasvol G, et al. Direct ex vivo analysis of antigen-specific IFN-γ secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol. 2001;167:5217-25.
17. Sester M, Sester U, Clauer P, Heine G, Mack U, Moll T, et al. Tuberculin skin testing underestimates a high prevalence of latent tuberculosis infection in hemodialysis patients. Kidney Int. 2004;65:1826-34.
18. Passalent L, Khan K, Richardson R, Wang J, Dedier H, Gardham M. Detecting latent tuberculosis infection in hemodialysis patients: a head to head comparison of the T.Spot.TB test, tuberculin skin test and a expert physician panel. Clin J Am Soc Nephrol. 2007;2:68-73.
19. Mow WS, Abreu-Martin MT, Papadakis KA, Pitcon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol. 2004;2:309-13.
20. Ponce de León D, Acevedo-Vázquez E, Sánchez-Torres A, Cucho M, Alfaro J, Perich R,